189 related articles for article (PubMed ID: 16787379)
21. Src and focal adhesion kinase as therapeutic targets in cancer.
Brunton VG; Frame MC
Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340
[TBL] [Abstract][Full Text] [Related]
22. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
Register AC; Chakraborty S; Maly DJ
Methods Mol Biol; 2017; 1636():79-89. PubMed ID: 28730474
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 4,6-substituted-(diaphenylamino)quinazolines as potent c-Src inhibitors.
Li JR; Li DD; Fang F; Du QR; Lin L; Sun J; Qian Y; Zhu HL
Org Biomol Chem; 2013 Dec; 11(48):8375-86. PubMed ID: 24178241
[TBL] [Abstract][Full Text] [Related]
24. Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.
Boschelli DH; Wang D; Wang Y; Wu B; Honores EE; Barrios Sosa AC; Chaudhary I; Golas J; Lucas J; Boschelli F
Bioorg Med Chem Lett; 2010 May; 20(9):2924-7. PubMed ID: 20363128
[TBL] [Abstract][Full Text] [Related]
25. Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain.
Johnson TK; Soellner MB
Bioconjug Chem; 2016 Jul; 27(7):1745-9. PubMed ID: 27266260
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
27. The role of Src in solid tumors.
Wheeler DL; Iida M; Dunn EF
Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
[TBL] [Abstract][Full Text] [Related]
28. An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase.
Ohkura K; Kawaguchi Y; Tatematsu Y; Uto Y; Hori H
Anticancer Res; 2016 Jul; 36(7):3645-9. PubMed ID: 27354635
[TBL] [Abstract][Full Text] [Related]
29. A hot spot for protein kinase inhibitor sensitivity.
Bishop AC
Chem Biol; 2004 May; 11(5):587-9. PubMed ID: 15157868
[TBL] [Abstract][Full Text] [Related]
30. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
31. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
Baselga J
Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
[No Abstract] [Full Text] [Related]
32. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.
Kim MP; Park SI; Kopetz S; Gallick GE
Cell Tissue Res; 2009 Jan; 335(1):249-59. PubMed ID: 18815812
[TBL] [Abstract][Full Text] [Related]
33. Src-family tyrosine kinases as therapeutic targets in advanced cancer.
Gelman IH
Front Biosci (Elite Ed); 2011 Jun; 3(3):801-7. PubMed ID: 21622091
[TBL] [Abstract][Full Text] [Related]
34. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
35. SRC: a century of science brought to the clinic.
Aleshin A; Finn RS
Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
[TBL] [Abstract][Full Text] [Related]
36. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
37. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
38. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
[TBL] [Abstract][Full Text] [Related]
39. [ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].
Klener P; Klener P
Klin Onkol; 2010; 23(4):203-9. PubMed ID: 20806817
[TBL] [Abstract][Full Text] [Related]
40. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.
Park SI; Shah AN; Zhang J; Gallick GE
Expert Opin Ther Targets; 2007 Sep; 11(9):1207-17. PubMed ID: 17845146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
